Seres Therapeutics, INC Form 4 insider transactions

Teresa L. Young, EVP, Chief Commercial & Strategy Officer at Seres Therapeutics, Inc., was granted 3,998 restricted stock units, vesting on November 15, 2025.

Seres Therapeutics, Inc. granted 3,998 Restricted Stock Units to Chief Scientific Officer and EVP Matthew R. Henn, aligning executive incentives with shareholder value.

Seres Therapeutics' EVP, Chief Commercial & Strategy Officer, Teresa L. Young, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Seres Therapeutics Director Eric D. Shaff reported the acquisition of common stock through RSU vesting and subsequent sale of shares to cover tax obligations under a pre-arranged 10b5-1 plan.

A Seres Therapeutics executive sold shares to cover tax obligations related to restricted stock unit vesting.

Seres Therapeutics' Chief Scientific Officer, Matthew R. Henn, sold 73 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Seres Therapeutics director Robert L. Rosiello was granted 10,000 stock options with an exercise price of $14.28, vesting quarterly over four years.

Seres Therapeutics, Inc. Director Dennis A. Ausiello was granted 6,452 stock options with an exercise price of $10.71, vesting quarterly over one year.

Seres Therapeutics, Inc. Director Stephen Berenson was granted 11,470 stock options with an exercise price of $10.71, vesting quarterly over one year.

Seres Therapeutics, Inc. Director Claire Fraser was granted 6,452 stock options with an exercise price of $10.71, vesting quarterly over one year.

Matthew Henn, Chief Scientific Officer and EVP of Seres Therapeutics, reports the vesting and selling of restricted stock units to cover taxes.

Teresa Young, EVP of Seres Therapeutics, reports the vesting and selling of restricted stock units to cover taxes, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Seres Therapeutics CEO Eric Shaff reports the acquisition and disposition of common stock and restricted stock units, including sales to cover taxes related to vesting.

Chief Legal Officer and EVP of Seres Therapeutics, Thomas DesRosier, reports the vesting and sale of restricted stock units to cover taxes.

Director Paul Biondi reports acquisition of 100,000 stock options in Seres Therapeutics.

Director Claire Fraser of Seres Therapeutics, Inc. [MCRB] was granted stock options to purchase 100,000 shares of common stock at an exercise price of $0.58 on April 10, 2025.

Director Kurt Graves acquired 100,000 stock options in Seres Therapeutics, Inc. on April 10, 2025.

Director Stephen Berenson acquired stock options in Seres Therapeutics, Inc.

Director Richard N. Kender acquired stock options for 100,000 shares of Seres Therapeutics, Inc. at an exercise price of $0.58 on April 10, 2025.

Director Dennis A. Ausiello acquired stock options for 100,000 shares of Seres Therapeutics common stock on April 10, 2025.

Director Dere Willard H. reports the acquisition of stock options in Seres Therapeutics, Inc.

Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, sold 3,338 shares of common stock at an average price of $0.8102 to cover taxes related to the vesting of restricted stock units.

Matthew Henn, Chief Scientific Officer and EVP of Seres Therapeutics, reports the sale of common stock to cover taxes related to vesting restricted stock units.

Seres Therapeutics CEO Eric Shaff reports the acquisition and disposal of common stock and restricted stock units, including sales to cover taxes related to vesting.

Chief Legal Officer and EVP Thomas DesRosier reports the acquisition and disposal of Seres Therapeutics (MCRB) common stock and restricted stock units.

Lisa von Moltke, Executive Vice President and Chief Medical Officer of Seres Therapeutics, reports the sale of common stock to cover taxes related to vesting restricted stock units.

Marella Thorell, EVP and Chief Financial Officer of Seres Therapeutics, acquires stock options for 650,000 shares.

Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, acquired 650,000 stock options on February 7, 2025.

Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, received stock options for 650,000 shares on February 7, 2025.

Seres Therapeutics CEO Eric D. Shaff was granted stock options for 1,950,000 shares on February 7, 2025, according to a Form 4 filing.